{"id":"W4404520549","doi":"10.1016/j.fpurol.2024.07.039","title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) dans le traitement de première ligne (1L) du carcinome rénal avancé (CCRa) : données de suivi à long terme de l’étude de phase 3 CheckMate 214","year":2024,"lang":"fr","type":"article","venue":"Progrès en Urologie - FMC","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ipilimumab; Medicine; Cancer research; Immunotherapy; Cancer; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002598976,0.0003379819,0.001580591,0.0003288434,0.0001818259,0.001110732,0.0003614936,0.0005630106,0.002857762],"category_scores_gemma":[0.002977439,0.0002583771,0.002655856,0.0003598016,0.0003455761,0.0007566873,0.000201714,0.001312514,0.0003907968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008703911,"about_ca_system_score_gemma":0.000697149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001726526,"about_ca_topic_score_gemma":0.005006164,"domain_scores_codex":[0.999236,0.0003692977,0.00008224436,0.0001178664,0.0001271816,0.00006748438],"domain_scores_gemma":[0.9985285,0.0008431317,0.0003413799,0.00008393957,0.00009457853,0.0001083539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.481847,0.004818246,0.02276822,0.006790196,0.02355736,0.00009517269,0.0002969751,0.003120121,0.0133336,0.0005461653,0.003553469,0.4392735],"study_design_scores_gemma":[0.2833483,0.343662,0.2147744,0.003743651,0.07777307,0.001255767,0.0005124696,0.006378159,0.01685799,0.001549186,0.04983173,0.0003132641],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8914647,0.1013759,0.0007911127,0.0007579873,0.0003016582,0.0003936039,0.001825184,0.00004969428,0.003040063],"genre_scores_gemma":[0.9761409,0.01853136,0.001062537,0.0007309279,0.0001516403,0.0002624734,0.001725688,0.00002177061,0.001372778],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002857762,"threshold_uncertainty_score":0.01374483,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03211837541477341,"score_gpt":0.2926767589863165,"score_spread":0.2605583835715431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}